Aberrant glycosylation of CD133 or Trop2 in prostate cancer stem cells may affect their folding and stability, resulting in incorrect protein assembly and abnormal signaling networks, thus promoting cancer growth [20]. The gene discussed is TACSTD2; the disease is prostate cancer.